1
|
Parker MJ, Lee H, Yao S, Irwin S, Hwang S, Belanger K, de Mare SW, Surgenor R, Yan L, Gee P, Morla S, Puyang X, Hsiao P, Zeng H, Zhu P, Korpal M, Dransfield P, Bolduc DM, Larsen NA. Identification of 2-Sulfonyl/Sulfonamide Pyrimidines as Covalent Inhibitors of WRN Using a Multiplexed High-Throughput Screening Assay. Biochemistry 2023. [PMID: 37403936 DOI: 10.1021/acs.biochem.2c00599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Werner syndrome protein (WRN) is a multifunctional enzyme with helicase, ATPase, and exonuclease activities that are necessary for numerous DNA-related transactions in the human cell. Recent studies identified WRN as a synthetic lethal target in cancers characterized by genomic microsatellite instability resulting from defects in DNA mismatch repair pathways. WRN's helicase activity is essential for the viability of these high microsatellite instability (MSI-H) cancers and thus presents a therapeutic opportunity. To this end, we developed a multiplexed high-throughput screening assay that monitors exonuclease, ATPase, and helicase activities of full-length WRN. This screening campaign led to the discovery of 2-sulfonyl/sulfonamide pyrimidine derivatives as novel covalent inhibitors of WRN helicase activity. The compounds are specific for WRN versus other human RecQ family members and show competitive behavior with ATP. Examination of these novel chemical probes established the sulfonamide NH group as a key driver of compound potency. One of the leading compounds, H3B-960, showed consistent activities in a range of assays (IC50 = 22 nM, KD = 40 nM, KI = 32 nM), and the most potent compound identified, H3B-968, has inhibitory activity IC50 ∼ 10 nM. These kinetic properties trend toward other known covalent druglike molecules. Our work provides a new avenue for screening WRN for inhibitors that may be adaptable to different therapeutic modalities such as targeted protein degradation, as well as a proof of concept for the inhibition of WRN helicase activity by covalent molecules.
Collapse
Affiliation(s)
- Mackenzie J Parker
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Hyelee Lee
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Shihua Yao
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Sean Irwin
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Sunil Hwang
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Kylie Belanger
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Sofia Woo de Mare
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Richard Surgenor
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Lu Yan
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Patricia Gee
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Shravan Morla
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Xiaoling Puyang
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Peng Hsiao
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Hao Zeng
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Ping Zhu
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Manav Korpal
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Paul Dransfield
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - David M Bolduc
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| | - Nicholas A Larsen
- H3 Biomedicine, Inc., 300 Technology Square, Suite 5, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
2
|
Irwin S, Karr C, Furman C, Tsai J, Gee P, Banka D, Wibowo AS, Dementiev AA, O'Shea M, Yang J, Lowe J, Mitchell L, Ruppel S, Fekkes P, Zhu P, Korpal M, Larsen NA. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists. J Biol Chem 2022; 298:102539. [PMID: 36179791 PMCID: PMC9626935 DOI: 10.1016/j.jbc.2022.102539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 09/20/2022] [Accepted: 09/23/2022] [Indexed: 11/15/2022] Open
Abstract
Recent studies have reported that the peroxisome proliferator–activated receptor gamma (PPARγ) pathway is activated in approximately 40% of patients with muscle-invasive bladder cancer. This led us to investigate pharmacological repression of PPARγ as a possible intervention strategy. Here, we characterize PPARγ antagonists and inverse agonists and find that the former behave as silent ligands, whereas inverse agonists (T0070907 and SR10221) repress downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines. To understand the mechanism, we determined the ternary crystal structure of PPARγ bound to T0070907 and the corepressor (co-R) peptide NCOR1. The structure shows that the AF-2 helix 12 (H12) rearranges to bind inside the ligand-binding domain, where it forms stabilizing interactions with the compound. This dramatic movement in H12 unveils a large interface for co-R binding. In contrast, the crystal structure of PPARγ bound to a SR10221 analog shows more subtle structural differences, where the compound binds and pushes H12 away from the ligand-binding domain to allow co-R binding. Interestingly, we found that both classes of compound promote recruitment of co-R proteins in biochemical assays but with distinct conformational changes in H12. We validate our structural models using both site-directed mutagenesis and chemical probes. Our findings offer new mechanistic insights into pharmacological modulation of PPARγ signaling.
Collapse
Affiliation(s)
- Sean Irwin
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Craig Karr
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Craig Furman
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Jennifer Tsai
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); Monta Rosa Therapeutics, Boston MA (present affiliation)
| | - Patricia Gee
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Deepti Banka
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Ardian S Wibowo
- Shamrock Structure, Woodridge IL (where work was performed); Helix Biostructures, Indianapolis IN (present affiliation)
| | - Alexey A Dementiev
- Shamrock Structure, Woodridge IL (where work was performed); Schrodinger Inc., Natick MA (present affiliation)
| | - Morgan O'Shea
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); C4 Therapeutics, Watertown MA (present affiliation)
| | - Joyce Yang
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); Blueprint Medicines, Cambridge MA (present affiliation)
| | - Jason Lowe
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); Foghorn Therapeutics, Cambridge MA (present affiliation)
| | - Lorna Mitchell
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); Certa Therapeutics, Melbourne VIC, Australia (present affiliation)
| | - Sabine Ruppel
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); Ikena Oncology, Boston MA (present affiliation)
| | - Peter Fekkes
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed); 54 Gene, Washington DC (present affiliation)
| | - Ping Zhu
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Manav Korpal
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed)
| | - Nicholas A Larsen
- H3 Biomedicine, 300 Technology Sq #5, Cambridge MA 02139 (where work was performed).
| |
Collapse
|
3
|
Furman C, Puyang X, Zhang Z, Wu ZJ, Banka D, Aithal KB, Albacker LA, Hao MH, Irwin S, Kim A, Montesion M, Moriarty AD, Murugesan K, Nguyen TV, Rimkunas V, Sahmoud T, Wick MJ, Yao S, Zhang X, Zeng H, Vaillancourt FH, Bolduc DM, Larsen N, Zheng GZ, Prajapati S, Zhu P, Korpal M. Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. Mol Cancer Ther 2022; 21:890-902. [PMID: 35642432 PMCID: PMC9381127 DOI: 10.1158/1535-7163.mct-21-0378] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 08/19/2021] [Accepted: 03/18/2022] [Indexed: 01/07/2023]
Abstract
Nearly 30% of patients with relapsed breast cancer present activating mutations in estrogen receptor alpha (ERα) that confer partial resistance to existing endocrine-based therapies. We previously reported the development of H3B-5942, a covalent ERα antagonist that engages cysteine-530 (C530) to achieve potency against both wild-type (ERαWT) and mutant ERα (ERαMUT). Anticipating that the emergence of C530 mutations could promote resistance to H3B-5942, we applied structure-based drug design to improve the potency of the core scaffold to further enhance the antagonistic activity in addition to covalent engagement. This effort led to the development of the clinical candidate H3B-6545, a covalent antagonist that is potent against both ERαWT/MUT, and maintains potency even in the context of ERα C530 mutations. H3B-6545 demonstrates significant activity and superiority over standard-of-care fulvestrant across a panel of ERαWT and ERαMUT palbociclib sensitive and resistant models. In summary, the compelling preclinical activity of H3B-6545 supports its further development for the potential treatment of endocrine therapy-resistant ERα+ breast cancer harboring wild-type or mutant ESR1, as demonstrated by the ongoing clinical trials (NCT03250676, NCT04568902, NCT04288089). SUMMARY H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.
Collapse
Affiliation(s)
- Craig Furman
- H3 Biomedicine Inc., Cambridge, Massachusetts.,Corresponding Authors: Craig Furman, H3 Biomedicine, 300 Technology Square, Cambridge, MA 02139. E-mail: ; Manav Korpal, ; and Ping Zhu,
| | | | | | | | | | - Kiran B. Aithal
- Aurigene Discovery Technologies Ltd, Bangalore, Karnataka, India
| | | | | | - Sean Irwin
- H3 Biomedicine Inc., Cambridge, Massachusetts
| | - Amy Kim
- H3 Biomedicine Inc., Cambridge, Massachusetts
| | | | | | | | | | | | | | | | - Shihua Yao
- H3 Biomedicine Inc., Cambridge, Massachusetts
| | - Xun Zhang
- H3 Biomedicine Inc., Cambridge, Massachusetts
| | - Hao Zeng
- H3 Biomedicine Inc., Cambridge, Massachusetts
| | | | | | | | | | | | - Ping Zhu
- H3 Biomedicine Inc., Cambridge, Massachusetts.,Corresponding Authors: Craig Furman, H3 Biomedicine, 300 Technology Square, Cambridge, MA 02139. E-mail: ; Manav Korpal, ; and Ping Zhu,
| | - Manav Korpal
- H3 Biomedicine Inc., Cambridge, Massachusetts.,Corresponding Authors: Craig Furman, H3 Biomedicine, 300 Technology Square, Cambridge, MA 02139. E-mail: ; Manav Korpal, ; and Ping Zhu,
| |
Collapse
|
4
|
Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Correa-Fernández J, Mateus E, Grange L, Webb D, Jacklin C, Irwin S, Mingolla S, Antonopoulou K, Makri S, Navarro-Compán V. AB1121 HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMDs THROUGHOUT THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2). Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe COVID-19 pandemic has generated uncertainties and concerns along with expectations and hopes that may be of relevance to patients with rheumatic diseases.ObjectivesThe aim of this study is to assess changes in the fears and hopes of patients with rheumatic diseases throughout the two phases of REUMAVID.MethodsREUMAVID is an international cross-sectional study collecting data through an online survey in seven European countries led by the Health & Territory Research group of the University of Seville, together with a multidisciplinary team including patient representatives, rheumatologists, and health researchers. Data were collected in two phases: Phase 1 (P1) between April-July 2020 and Phase 2 (P2) between February-April 2021. Demographics, health behaviours, employment status, access to healthcare services, disease characteristics, WHO-5 Well-Being Index and Hospital Anxiety and Depression Scale (HADS). Participants rated a series of fears (infection, medication consequences, lack of medication, impact on healthcare, lost job, civil disorder) on a scale from zero (“no concern at all”) to five (“extremely concerned”) and hopes (treatment/vaccine availability, going outside, travel, economic situation, treatment continuation, health status) on a scale from zero (“no hopeful at all”) to five (“extremely hopeful”). Descriptive analysis and Mann-Whitney test were used to explore fears and hopes in both phases of REUMAVID.ResultsA total of 3,802 participants were recruited across both phases in REUMAVID with comparable demographic characteristics: mean age 52.6 (P1) vs. 55.0 years (P2), 80.2% female (P1) vs. 83.7% (P2), 69.6% married (P1) vs. 68.3% (P2), and 48.6% university educated (P1) vs. 47.8% (P2). Most prevalent RMD was axial spondyloarthritis in P1 (37.2%), and rheumatoid arthritis in P2 (53.1%).In P1 and P2 the major concern was the impact on healthcare in the future (3.1 and 3.2 out of 5, p=0.051). Compared to P1, patients in P2 had less fears about RMD medications not reaching the country (2.4 vs. 1.9, p<0.001), civil disorders (2.0 vs. 1.8, p=0.001), or losing their jobs (1.4 vs. 1.5, p=0.003). Comparing hopes with P1, patients in P2 had greater hopes about availability of treatments or vaccines suitable for COVID-19 (3.2 vs. 3.9, p<0.001), to be able to go out as before the pandemic (3.1 vs. 3.5, p<0.001), to be able to travel as before the pandemic (2.8 vs. 3.3, p<0.001), maintain and even improve the current economic situation after the pandemic (2.6 vs. 3.0, p<0.001), and to be able to continue their treatment as usual (3.8 vs. 3.8, p=0.049; Table 1)Table 1.Bivariate analysis of patients’ fears and hopes in both phases of REUMAVID (N= 3,802, unless specify)Mean ± SDP-valueFirst Phasen= 1,800Second phasen= 2,002FearsImpact on healthcare in the future, n= 3,6533.1 ± 1.63.2 ± 1.60.051Treatment taken could make you more likely to get serious illness from COVID-19 infection, n= 3,6512.8 ± 1.82.9 ± 1.80.160More likely to be infected due to the condition, n= 3,6492.8 ± 1.72.9 ± 1.70.040Lack of medication, n= 3,6562.4 ± 1.81.9 ± 1.8<0.001Civil disorder, n= 3,6342.0 ± 1.61.8 ± 1.70.001Lost job, n= 3,5661.5 ± 1.91.4 ± 1.90.003HopesAvailability of a treatment or vaccine suitable for COVID-19, n= 3,3183.2 ± 1.53.9 ± 1.3<0.001*Continue treatment as usual, n= 3,3063.7 ± 1.43.8 ± 1.30.049*Go out as before the COVID-19 pandemic, n= 3,3183.1 ± 1.53.5 ± 1.4<0.001*Don’t get infected with COVID-19 and continue in the same health, n= 3,2803.5 ± 1.53.5 ± 1.50.696Travel as before the COVID-19 pandemic, n= 3,3112.8 ± 1.63.3 ± 1.5<0.001*Maintain or improve economic situation after the COVID-19 pandemic, n= 3,3102.6 ± 1.73.0 ± 1.7<0.001*ConclusionDuring the first phase of REUMAVID at the beginning of the pandemic, patients with RMDs were more fearful and less hopeful compared to the second phase. These fears were notable in terms of lack of medication for their RMD, while during the second phase, patients were hopeful of a treatment or vaccine against COVID-19, and of being able to go out and travel as before.AcknowledgementsThis study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League for People with Rheumatism (CYLPER) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients’ Forum (FEP), UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASS), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.Disclosure of InterestsMarco Garrido-Cumbrera Grant/research support from: has a research collaboration with and provides services to Novartis Pharma AG, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Laura Christen Employee of: Novartis Pharma AG, José Correa-Fernández: None declared, Elsa Mateus Grant/research support from: Pfizer, grants from Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmakern and GAfPA, LAURENT GRANGE: None declared, Dale Webb Grant/research support from: AbbVie, Biogen, Janssen, Lilly, Novartis and UCB, Clare Jacklin Grant/research support from: Abbvie, Amgen, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi and UCB, Shantel Irwin: None declared, Serena Mingolla: None declared, KATY ANTONOPOULOU: None declared, Souzi Makri Grant/research support from: Novartis, GSK and Bayer, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB
Collapse
|
5
|
Jacobs D, Harvey J, Campbell N, Gardiner L, Espino K, Ha Nguyet H, Baker-Jones M, Hatton A, Irwin S. Corrigendum to ‘411. Outcomes of SWSLHD Nurse Led Cardiac Rehabilitation Programs: Uptake and Completion Rates for 2019’ [Heart, Lung and Circulation, Volume 30 Supplement 3 (2021) Page S281]. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2021.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Chong SMY, Hung RKY, Gwozdz A, Irwin S, Eastbury J, Cross T, Ahmed K, Taylor C, Goldenberg SD, Sanderson J, Olsburgh J. 30-Day postoperative COVID-19 outcomes in 398 patients from regional hospitals utilising a designated COVID-19 minimal surgical site pathway. Ann R Coll Surg Engl 2021; 103:395-403. [PMID: 33956529 PMCID: PMC10335038 DOI: 10.1308/rcsann.2020.7072] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/13/2020] [Indexed: 12/14/2022] Open
Abstract
INTRODUCTION Postoperative pulmonary complications and mortality rates during the COVID-19 pandemic have been higher than expected, leading to mass cancellation of elective operating in the UK. To minimise this, the Guy's and St Thomas' Hospital NHS Foundation Trust elective surgery hub and the executive team at London Bridge Hospital (LBH) created an elective operating framework at LBH, a COVID-19 minimal site, in which patients self-isolated for two weeks and proceeded with surgery only following a negative preoperative SARS-CoV-2 polymerase chain reaction swab. The aim was to determine the rates of rates of postoperative COVID-19 infection. METHODS The collaboration involved three large hospital trusts, covering the geographic area of south-east London. All patients were referred to LBH for elective surgery. Patients were followed up by telephone interview at four weeks postoperatively. RESULTS Three hundred and ninety-eight patients from 13 surgical specialties were included in the analysis. The median age was 60 (IQR 29-71) years. Sixty-three per cent (252/398) were female. In total, 78.4% of patients had an American Society of Anesthesiologists grade of 1-2 and the average BMI was 27.2 (IQR 23.7-31.8) kg/m2. Some 83.6% (336/402) were 'major' operations. The rate of COVID-19-related death in our cohort was 0.25% (1/398). Overall, there was a 1.26% (5/398) 30-day postoperative all-cause mortality rate. Seven patients (1.76%) reported COVID-19 symptoms, but none attended the emergency department or were readmitted to hospital as a result. CONCLUSION The risk of contracting COVID-19 in our elective operating framework was very low. We demonstrate that high-volume major surgery is safe, even at the peak of the pandemic, if patients are screened appropriately preoperatively.
Collapse
Affiliation(s)
| | | | | | - S Irwin
- Guy’s and St Thomas’ Hospital NHS Foundation Trust, UK
| | | | | | | | - C Taylor
- Guy’s and St Thomas’ Hospital NHS Foundation Trust, UK
| | - SD Goldenberg
- Guy’s and St Thomas’ Hospital NHS Foundation Trust, UK
| | - J Sanderson
- Guy’s and St Thomas’ Hospital NHS Foundation Trust, UK
| | - J Olsburgh
- Guy’s and St Thomas’ Hospital NHS Foundation Trust, UK
| |
Collapse
|
7
|
Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Carmona L, Correa-Fernández J, Sanz-Gómez S, Plazuelo-Ramos P, Makri S, Mateus E, Mingolla S, Antonopoulou K, Grange L, Jacklin C, Webb D, Irwin S, Navarro-Compán V. AB0677 GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The COVID-19 pandemic has impacted health, lifestyle, treatment and healthcare of European patients with rheumatic and musculoskeletal diseases (RMDs).Objectives:The aim is to evaluate gender differences on the impact of the first wave of the COVID-19 pandemic in the wellbeing, life habits, treatment, and healthcare access of European patients with RMDs.Methods:REUMAVID is an international collaboration led by the Health & Territory Research at the University of Seville, together with a multidisciplinary team including patient organisations and rheumatologists. This cross-sectional study consisting of an online survey gathering data from 1,800 patients with a diagnosis of 15 RMDs, recruited by patient organisations in Cyprus, France, Greece, Italy, Portugal, Spain, and the United Kingdom during the first phase of the pandemic (April-July 2020). Mann-Whitney and χ2 tests were used to analyse differences between gender regarding sociodemographic characteristics, life style, treatment, healthcare, and patient-reported outcomes.Results:1,797 patients were included in this analysis. 80.2% were female and a mean age of 52.6 years. The most common diagnosis was inflammatory arthritis (81.7% male vs 73.8% female). There was a higher prevalence of fibromyalgia among females (20% vs 7.0% male). Overall, females reported worse self-perceived health (67.0% vs 51.4%, p<0.001), higher risk of anxiety (59.5% vs 48.1%, p<0.001), and depression (48.0% vs 37.2%, p<0.001). Females reported a greater increase in smoking (26.5% vs 17.5%, p=0.001), although they were less likely to drink alcohol (34.5% vs 25.4%, p=0.013), and also engaged less in physical activity (53.0% vs 60.3%, p=0.045). Overall, females were more likely to keep their scheduled rheumatology appointment (43.3% vs 34.1% of males (p=0.049; Table 1) with a higher proportion of females having their rheumatic treatment changed (17.0% vs 10.7%, p=0.005).Conclusion:The first wave of the COVID-19 pandemic and the containment measures have worsened self-perceived health status of patients with RMDs, affecting genders differently. Females reported worse psychological health and life habits such as increased smoking and reduced physical activity, while males increased their alcohol consumption and were less likely to attend their rheumatology appointments.Table 1.Bivariate analysis by gender (N= 1,797 unless specify)Mean ± SD or n (%)P- valueMale(N= 355)Female(N= 1,442)Sociodemographic characteristicsDiseaseInflammatory arthritis1290 (81.7)1,064 (73.8)Fibromyalgia25 (7.0)287 (19.9)Connective tissue disease218 (5.1)195 (13.5)Osteoarthritis52 (14.6)255 (17.7)Osteoporosis10 (2.8)104 (7.2)Vasculitis37 (2.0)29 (2.0)SAPHO1 (0.3)14 (1.0)Age, years52.8 ± 14.252.5 ± 12.90.896Educational levelUniversity162 (45.6)711 (49.3)0.215Marital statusMarried or in relationship269 (75.8)983 (68.2)0.002*Member of a Patient organisation, N=1,795Yes188 (53.0)559 (38.8)<0.001*Patient-reported outcomesHADS Anxiety, N=1,766Risk168 (48.1)843 (59.5)<0.001*HADS Depression, N=1,766Risk130 (37.2)680 (48.0)<0.001*Wellbeing, N=1,774WHO-5 ≤ 50188 (53.4)681 (47.9)0.064Self-perceived health, N=1,783Fair or bad182 (51.4)958 (67.0)<0.001*Change in health status during COVID-19 pandemic, N=1,783Worse333 (94.1)1,339 (93.7)0.799Life style during COVID-19 pandemicSmoking, N=555More than before20 (17.5)117 (26.5)0.001*Alcohol consumption, N=1,083Quit drinking71 (25.4)277 (34.5)0.013Physical activity, N=1,126Yes144 (60.3)470 (53.0)0.045*Treatment and healthcareAble to meet rheumatologist, N= 721No89 (65.9)332 (56.7)0.049*Access to GP, N=688No43 (39.4)248 (42.8)0.5121Including: Axial Spondyloarthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Gout and Peripheral Spondyloarthritis; 2Including: Systemic Lupus Erythematosus, Sjögren’s Syndrome, Systemic Sclerosis and Myositis; 3Including: Polymyalgia Rheumatic and Vasculitis or Arteritis.Acknowledgements:This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League Against Rheumatism (CYPLAR) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients’ Forum (FEP), UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASS), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.Disclosure of Interests:Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Janssen and Novartis, Laura Christen Employee of: Novartis Pharma AG, Loreto Carmona: None declared, José Correa-Fernández: None declared, Sergio Sanz-Gómez: None declared, Pedro Plazuelo-Ramos: None declared, Souzi Makri Grant/research support from: Novartis, GSK and Bayer, Elsa Mateus Grant/research support from: Pfizer, grants from Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmakern, GAfPA., Serena Mingolla: None declared, KATY ANTONOPOULOU: None declared, LAURENT GRANGE: None declared, Clare Jacklin Grant/research support from: Abbvie, Amgen, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi & UCB., Dale Webb Grant/research support from: AbbVie, Biogen, Janssen, Lilly, Novartis and UCB., Shantel Irwin: None declared, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB
Collapse
|
8
|
Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Carmona L, Correa-Fernández J, Sanz-Gómez S, Plazuelo-Ramos P, Grange L, Webb D, Irwin S, Jacklin C, Makri S, Mateus E, Mingolla S, Antonopoulou K, Navarro-Compán V. POS1213 IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The COVID-19 pandemic has impacted the wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs).Objectives:The aim is to assess emotional well-being and its associated factors in patients with RMDs during the first wave of the COVID-19 pandemic.Methods:REUMAVID is an international collaboration led by the Health & Territory Research group at the University of Seville, together with a multidisciplinary team including patient organisations and rheumatologists. This cross-sectional study consisting of an online survey gathering data from patients with a diagnosis of 15 RMDs in Cyprus, France, Greece, Italy, Portugal, Spain, and the United Kingdom. 1,800 participants were recruited by patient organisations. Data was collected between April and July 2020. Participants were divided into two groups: 1) Participants with poor wellbeing (World Health Organization-Five Wellbeing Index (WHO-5) ≤ 50), 2) Participants with good wellbeing (WHO-5 >50). The Mann-Whitney and χ2 tests were used to analyse possible relations between sociodemographic characteristics, lifestyle, and outdoor contact with wellbeing during the first wave of the COVID-19 pandemic. Univariate and multivariate binary logistic regression was used to determine the impact of the independent variables associated with poor wellbeing.Results:1,777 patients with 15 different RMDs were included. The mean age was 52.7, 80.2% female, 48.7% had a university degree, and 69.7% were married or in a relationship. The most frequent diagnoses were inflammatory arthritis (75.4%). 49.0% reported poor wellbeing. 57.7% of patients who belonged to a patient organisation reported good wellbeing (vs 46.3% who did not, p<0.001). Those who reported poor wellbeing had higher disease activity (51.4% vs 41.3%, p<0.001), a higher risk of anxiety (54.3% vs 41.7%, p<0.001) and depression (57.0% vs 42.1%, p<0.001), and poorer self-perceived health (53.0% vs 41.8%, p<0.001), compared to those who did not. A higher proportion of those who engaged in physical activity presented good wellbeing (54.0% vs 46.5%, p=0.012). 57.4% of the patients who were unable to attend their appointment with their rheumatologist reported poor wellbeing, compared to 48.2% who did attend (p=0.027). Patients who did not walk outside (56.2%) or who lacked elements in their home to facilitate outside contact (63.3%) experienced poor wellbeing (p<0.001). The factors associated with poor wellbeing were lack of elements in the home enabling contact with the outside world (OR=2.10), not belonging to a patient organisation (OR=1.51), risk of depression (OR=1.49), and not walking outside (OR=1.36) during the COVID-19 pandemic (Table 1).Conclusion:Almost half of the patients with RMDs reported poor emotional wellbeing during the first wave of the COVID-19 pandemic. The lack of elements in the home that facilitate outdoor contact, not belonging to a patient organisation, the presence of anxiety, and not walking outside during the pandemic increase the probability of poor emotional well-being. These results highlight the importance of environmental factors and the role of patient organisations in addressing the effects of the pandemic and its containment measures.Table 1.Logistic regression for poor wellbeing WHO-5 (N=1,104)Univariate logistic analysisMultivariate logistic analysisOR95% CI1OR95% CI1Patient organisation. Non-member1.571.30, 1.891.511.18, 1.93Disease activity (VAS ≥ 4)1.501.21, 1.861.160.85, 1.56Risk of anxiety (HADs, 0-21)1.671.38, 2.021.200.92, 1.58Risk of depression (HADs, 0-21)1.831.51, 2.211.491.12, 1.99Self-reported health. Fair to very bad1.581.30, 1.911.260.94, 1.68Change in health status. Worse1.271.06, 1.531.050.80, 1.38Physical activity. No1.351.07, 1.711.080.83, 1.40Talked with rheumatologist during the pandemic. No1.451.04, 2.031.040.68, 1.61Walk outside during COVID-19 pandemic. No1.471.19, 1.831.361.02, 1.81Element in home with outdoor contact. No1.931.42, 2.622.101.41, 3.15195% CI for test H0: OR = 1Acknowledgements:This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League Against Rheumatism (CYPLAR) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients’ Forum (FEP), UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASS), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.Disclosure of Interests:Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB., Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Laura Christen Employee of: Novartis Pharma AG, Loreto Carmona: None declared, José Correa-Fernández: None declared, Sergio Sanz-Gómez: None declared, Pedro Plazuelo-Ramos: None declared, LAURENT GRANGE: None declared, Dale Webb Grant/research support from: AbbVie, Biogen, Janssen, Lilly, Novartis and UCB., Shantel Irwin: None declared, Clare Jacklin Grant/research support from: has received grant funding from Abbvie, Amgen, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi & UCB, Souzi Makri Grant/research support from: Novartis, GSK and Bayer., Elsa Mateus Grant/research support from: Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmakern, GAfPA., Serena Mingolla: None declared, KATY ANTONOPOULOU: None declared, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB.
Collapse
|
9
|
Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Carmona L, Correa-Fernández J, Sanz-Gómez S, Plazuelo-Ramos P, Webb D, Jacklin C, Irwin S, Grange L, Makri S, Mateus E, Mingolla S, Antonopoulou K, Navarro-Compán V. AB0676 FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The first wave of the COVID-19 pandemic led to a rapidly evolving global crisis characterized by major uncertainty.Objectives:The objective is to assess COVID-19-related fears and hopes in patients with rheumatic and musculoskeletal diseases (RMDs) during the first wave of the pandemic.Methods:REUMAVID is an international collaboration led by the Health & Territory Research group at the University of Seville, together with a multidisciplinary team including patient organisations and rheumatologists. This cross-sectional study consisting of an online survey gathering data from 1,800 patients with a diagnosis of 15 RMDs recruited by patient organisations in Cyprus, France, Greece, Italy, Portugal, Spain and, the United Kingdom. Data are collected in two phases, the first phase between April and July 2020, the second in 2021. Participants rated a series of fears (infection, medication consequences, lack of medication, impact on healthcare, job loss, civil disorder) on a Likert scale from zero (“no concern at all”) to five (“extremely concerned”) and their hopes (treatment/vaccine availability, going outside, travel, economic situation, treatment continuation, health status) on a Likert scale from zero (“not hopeful at all”) to five (“extremely hopeful”). The Mann-Whitney and Kruskal-Wallis tests were used to analyse the different fears and hopes according to socio-demographics characteristics, disease and health status.Results:1,800 patients participated in the first phase of REUMAVID. The most frequent RMDs group was inflammatory arthritis (75.4%), the mean age was 52.6 years and 80.1% were female. The most important fear for patients was the impact of the COVID-19 pandemic on healthcare (3.1 out of 5), particularly for those younger in age (3.0 vs 3.2, p=0.004), female gender (3.2 vs 2. 9 of men, p=0.003), experiencing greater pain (3.1 vs 2.8, p=0.007), with higher risk of anxiety (3.3 vs 2.9 of without anxiety, p<0.001) and depression (3.3 vs 2.9 without depression, p<0.001). The possible impact of anti-rheumatic medication and the development of severe disease if they became infected with COVID-19,was mostly feared (2.8 out of 5), by those receiving biological therapy (3.1 vs 2.5 not biological therapy, p<0.001) or those with underlying anxiety (2.9 vs 2.6 without anxiety, p=0.007). The risk of contracting COVID-19 due to their condition (2.8 out of 5), was especially feared by those with vasculitis (3.2 out of 5), who were female (2.9 vs 2.5, p<0.001), using biologics (2. 9 vs 2.7 of no use, p=0.003), in greater pain (2.8 vs 2.4, p<0.001), with a risk of anxiety (3.0 vs 2.6 without anxiety, p=0.004), and risk of depression (3.0 vs 2.6 without depression, p<0.001). The major hopes were to be able to continue with their treatment as usual (3.7 out of 5), particularly for those taking biologics (3.8 vs 3.6 not taking, p=0.026), those with a better well-being (3.8 vs 3.6 with worse well-being, p=0.021), without anxiety (3.8 vs 3.6 at risk, p=0.004) and without depression (3.8 vs 3.6 at risk, p=0.007). Hoping not to become infected with COVID-19 and to maintain the same health status, were especially those who were older (3.6 vs 3.4 p=0.018) without anxiety (3.4 vs 3.6 at risk, p=0.005), and without depression (3.6 vs 3.4 at risk, p=0.006). Another important hope was the availability of a treatment or vaccine for COVID-19, which was important for patients experiencing better well-being (3.3 vs 3.0 with worse well-being, p<0.001; Figure 1).Conclusion:The outstanding COVID-19-related fear expressed by European patients with RMDs was its impact on healthcare, while the greatest hope was to be able to continue treatment. Younger patients reported more fears while older patients were more hopeful. Those receiving biologics had greater fears and hopes associated with their treatment. In addition, patients at risk of mental disorders presented greater fears and less hopes.Figure 1.Fears and Hopes of REUMAVID participantsAcknowledgements:This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League Against Rheumatism (CYPLAR) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients’ Forum (FEP), UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASS), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.Disclosure of Interests:Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Janssen and Novartis, Laura Christen Employee of: Novartis Pharma AG, Loreto Carmona: None declared, José Correa-Fernández: None declared, Sergio Sanz-Gómez: None declared, Pedro Plazuelo-Ramos: None declared, Dale Webb Grant/research support from: AbbVie, Biogen, Janssen, Lilly, Novartis and UCB., Clare Jacklin Grant/research support from: Abbvie, Amgen, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi & UCB, Shantel Irwin: None declared, LAURENT GRANGE: None declared, Souzi Makri Grant/research support from: Novartis, GSK and Bayer., Elsa Mateus Grant/research support from: Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmakern, GAfPA., Serena Mingolla: None declared, KATY ANTONOPOULOU: None declared, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB
Collapse
|
10
|
Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Carmona L, Correa-Fernández J, Sanz-Gómez S, Mateus E, Makri S, Plazuelo-Ramos P, Grange L, Mingolla S, Antonopoulou K, Webb D, Jacklin C, Irwin S, Navarro-Compán V. AB0675 COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The COVID-19 pandemic has impacted every aspect of life of European patients with rheumatic and musculoskeletal diseases (RMDs).Objectives:The aim is to evaluate country differences on the impact of the first wave of the COVID-19 pandemic on life habits, healthcare access, health status, mental health and wellbeing in European patients with RMDs.Methods:REUMAVID is an international collaboration led by the Health & Territory Research group at the University of Seville, together with a multidisciplinary team including patient organisations and rheumatologists. This cross-sectional study consisting of an online survey gathering data from patients with a diagnosis of 15 RMDs in Cyprus, France, Greece, Italy, Portugal, Spain, and the United Kingdom. Participants were recruited by patient organisations (April-July 2020). The Kruskal-Wallis and χ2 tests were used to analyse differences between countries and independent variables.Results:1,800 patients participated in the first wave of the COVID-19 pandemic (REUMAVID). 37.8% of Spanish patients increased their smoking consumption during the pandemic followed by Cyprus (32.1%) and Portugal (31.0%), while alcohol consumption was higher in the UK (36.3%) and France (27.0%). 82.3% of patients in Spain unable to attend their appointment with their rheumatologist, either due to cancellations or other personal reasons. Access to primary care was most limited in Portugal and Italy, where only 45.0% and 51.6% got access. 61.9% in Italy and 53.3% in Spain experienced a worsening of their health during the pandemic. 68.5% in Spain and 67.8% in Portugal were at risk of anxiety. The highest proportion at risk of depression was found in Greece (55.4%), Cyprus (55.1%), and Italy (54.8%). 66.9% of patients in Spain reported poor wellbeing, compared to 23.8% in Italy and 30.1% in Portugal (Table 1).Conclusion:The first wave of the pandemic and the related containment measures heterogeneously affected patients with RMDs across European countries, who overall increased harmful habits, experienced more difficulties in accessing healthcare and, reported poor mental health and well-being.Table 1.Bivariate analysis between European countries (N=1,800, unless specified)Mean ± SD or n (%)UKn: 558Spainn: 464Francen: 229Greecen: 57Cyprusn: 101Italyn: 127Portugaln: 264- Inflammatory arthritis1509 (91.2)402 (86.6)147 (64.2)33 (57.9)57 (56.4)89 (70.1)120 (45.5)- Fibromyalgia53 (9.5)14 (3.0)26 (11.4)14 (24.6)28 (27.7)53 (41.7)124 (47.0)- Connective tissue disease236 (6.5)15 (3.2)13 (5.7)25 (43.9)33 (32.7)30 (23.6)61 (23.1)- Osteoarthritis140 (25.1)29 (6.3)102 (44.5)0 (0.0)8 (7.9)15 (11.8)13 (4.9)- Osteoporosis50 (9.0)3 (0.6)20 (8.7)2 (3.5)9 (8.9)18 (14.2)12 (4.5)- Vasculitis39 (1.6)1 (0.2)6 (2.6)3 (5.3)3 (3.0)5 (3.9)9 (3.4)- Sapho (only France)15 (6.6)Smoking, More than before.N= 55616 (10.3)48 (37.8)22 (24.7)8 (23.5)9 (32.1)8 (20.5)26 (31.0)Alcohol consumption, More than before. N= 1,08599 (36.3)48 (10.3)27 (27.0)4 (7.0)4 (4.0)4 (13.3)11 (18.3)Unable to meet rheumatologist. N= 72283 (48.8)186 (82.3)27 (30.3)18 (64.3)22 (51.2)9 (31.0)77 (56.2)Access to primary care. N= 68987 (76.3)65 (67.7)32 (76.2)14 (60.9)17 (60.7)65 (51.6)117 (45.0)Change in health status, Much worse or worse. N=1,786214 (38.4)245 (53.3)98 (43.0)24 (42.9)38 (38.4)78 (61.9)135 (51.9)WHO-5. Poor well-being (≤50).N= 1,777292 (52.5)303 (66.9)100 (43.9)21 (37.5)46 (46.5)30 (23.8)78 (30.1)Risk of anxiety. N= 1,769241 (43.6)309 (68.5)118 (52.0)31 (55.4)61 (62.2)78 (61.9)175 (67.8)Risk of depression. N= 1,769186 (33.6)232 (51.4)101 (44.5)31 (55.4)54 (55.1)69 (54.8)138 (53.8)Note: all relations were significant at the 0.001 level. 1Including: Axial Spondyloarthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Gout and Peripheral Spondyloarthritis; 2Including: Systemic Lupus Erythematosus, Sjögren’s Syndrome, Systemic Sclerosis and Myositis; 3Including: Polymyalgia Rheumatic and Vasculitis or Arteritis.Acknowledgements:This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League Against Rheumatism (CYPLAR) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients’ Forum (FEP), UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASS), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.Disclosure of Interests:Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Janssen and Novartis, Laura Christen Employee of: Novartis Pharma AG, Loreto Carmona: None declared, José Correa-Fernández: None declared, Sergio Sanz-Gómez: None declared, Elsa Mateus Grant/research support from: Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmakern, GAfPA., Souzi Makri Grant/research support from: Novartis, GSK and Bayer., Pedro Plazuelo-Ramos: None declared, LAURENT GRANGE: None declared, Serena Mingolla: None declared, KATY ANTONOPOULOU: None declared, Dale Webb Grant/research support from: AbbVie, Biogen, Janssen, Lilly, Novartis and UCB, Clare Jacklin Grant/research support from: Abbvie, Amgen, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi & UCB, Shantel Irwin: None declared, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, and UCB
Collapse
|
11
|
Korpal M, Furman C, Puyang X, Zhang Z, Wu Z, Banka D, Das S, Destenaves B, Gao L, Hamilton E, Hao MH, Irwin S, Johnston S, Joshi JJ, Juric D, Kim A, Nguyen TV, Pipas M, Pluard T, Rimkunas V, Rioux N, Schindler J, Smith P, Thomas M, Wang J, Wang JS, Warmuth M, Yao H, Yao S, Yu L, Vaillancourt FH, Bolduc DM, Larsen NA, Zheng G, Prajapati S, Sahmoud T, Gualberto A, Zhu P. Abstract PS12-23: Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps12-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mutations in the ligand-binding domain of estrogen receptor alpha (ERα) are detected in up to 30% of patients (pts) who have relapsed or progressed during endocrine therapy. By favoring the agonistic conformation in ERα, these hotspot mutations promote ligand-independent activation of ERα and confer partial resistance to ER-directed therapies. Of the various hotspot mutations, Y537S is the most constitutively active, promotes the greatest resistance phenotype to current endocrine therapies, and is associated with the worst prognosis relative to other ERα mutations. The fact that current ER-directed therapies have limited activity in the ERα mutant setting emphasizes the critical need to develop the next generation of high affinity ER antagonists that can overcome the aberrant activity of mutant ERα.
H3B-6545 is a first-in-class selective ERα covalent antagonist (SERCA) which inactivates both wild-type and mutant ERα by irreversibly engaging cysteine-530. Biophysical and biochemical analyses confirm the long residence time achieved by covalent binding, and cellular analyses confirm the selectivity and single-digit nanomolar potency of H3B-6545 across a panel of ERαWT and ERαMUT breast cancer cell lines. H3B-6545 as a monotherapy demonstrates superior anti-tumor activity relative to fulvestrant across a set of CDK4/6 inhibitor naïve ERαWT and ERαY537S cell line-derived xenograft (CDX)/patient-derived xenograft (PDX) models, with regressions being noted in both the ERαWT and ERαMUT settings. Furthermore, H3B-6545 continues to demonstrate single agent activity in CDK4/6 inhibitor-resistant ERαWT and ERαY537S PDX models, in which fulvestrant fails to demonstrate significant anti-tumor activity. Lastly, improved activity and duration of response are noted when H3B-6545 is combined with several targeted therapies, including CDK4/6 inhibitors palbociclib and abemaciclib across a range of ERαWT and ERαY537S CDX/PDX models.
The phase I-II trial (NCT03250676) enrolled 130 heavily pretreated pts with ER+, HER2- metastatic breast cancer, including 12 pts harboring high allele frequency clonal ESR1 Y537S circulating tumor DNA (ctDNA). Median number of prior therapy in the metastatic setting was 3 (range: 1-10). Consistent with the preclinical data, H3B-6545 demonstrated promising clinical activity among these pts with clonal Y537S mutations, with a median progression free survival of 7.3 months and an overall response rate of 25% (3 confirmed partial responses).
In summary, these compelling preclinical data coupled with emerging clinical activity in heavily pretreated poor prognosis pts support further development of H3B-6545 as monotherapy or combination treatment.
Citation Format: Manav Korpal, Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua Wu, Deepti Banka, Subhasree Das, Benoit Destenaves, Lei Gao, Erika Hamilton, Ming-Hong Hao, Sean Irwin, Stephen Johnston, Jaya J Joshi, Dejan Juric, Amy Kim, Tuong-Vi Nguyen, Marc Pipas, Timothy Pluard, Victoria Rimkunas, Nathalie Rioux, Joanne Schindler, Peter Smith, Michael Thomas, John Wang, Judy S Wang, Markus Warmuth, Huilan Yao, Shihua Yao, Lihua Yu, Frédéric H Vaillancourt, David M Bolduc, Nicholas A Larsen, GuoZhu Zheng, Sudeep Prajapati, Tarek Sahmoud, Antonio Gualberto, Ping Zhu. Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS12-23.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Lei Gao
- 2Eisai Inc., Woodcliff Lake, NJ
| | - Erika Hamilton
- 3Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
| | | | | | | | | | | | - Amy Kim
- 1H3 Biomedicine Inc, Cambridge, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Lihua Yu
- 1H3 Biomedicine Inc, Cambridge, MA
| | | | | | | | | | | | | | | | - Ping Zhu
- 1H3 Biomedicine Inc, Cambridge, MA
| |
Collapse
|
12
|
Brawn RA, Cook A, Omoto K, Ke J, Karr C, Colombo F, Virrankoski M, Prajapati S, Reynolds D, Bolduc DM, Nguyen TV, Gee P, Borrelli D, Caleb B, Yao S, Irwin S, Larsen NA, Selvaraj A, Zhao X, Ioannidis S. Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3. ACS Med Chem Lett 2021; 12:93-98. [PMID: 33488969 DOI: 10.1021/acsmedchemlett.0c00517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 11/25/2020] [Indexed: 11/28/2022] Open
Abstract
Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple drugs approved or entering late stage clinical trials. A limitation of current inhibitors is vulnerability to gatekeeper resistance mutations. Using a combination of targeted high-throughput screening and structure-based drug design, we have developed a series of aminopyrazole based FGFR inhibitors that covalently target a cysteine residue on the P-loop of the kinase. The inhibitors show excellent activity against the wild-type and gatekeeper mutant versions of the enzymes. Further optimization using SAR analysis and structure-based drug design led to analogues with improved potency and drug metabolism and pharmacokinetics properties.
Collapse
Affiliation(s)
- Ryan A. Brawn
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Andrew Cook
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Kiyoyuki Omoto
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Jiyuan Ke
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Craig Karr
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Federico Colombo
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Milena Virrankoski
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Sudeep Prajapati
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Dominic Reynolds
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - David M. Bolduc
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Tuong-Vi Nguyen
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Patricia Gee
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Deanna Borrelli
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Benjamin Caleb
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Shihua Yao
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Sean Irwin
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Nicholas A. Larsen
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Anand Selvaraj
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Xuesong Zhao
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Stephanos Ioannidis
- H3 Biomedicine, 300 Technology Square, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Jacobs D, Harvey J, Campbell N, Gardiner L, Espino K, Ha Nguyet H, Baker-Jones M, Hatton A, Irwin S. Outcomes of SWSLHD Nurse Led Cardiac Rehabilitation Programs: Uptake and Completion Rates for 2019. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Irwin S, Flaherty MS, Carolsfeld J. The contribution of small-scale, privately owned tropical aquaculture to food security and dietary diversity in Bolivia. Food Secur 2020. [DOI: 10.1007/s12571-020-01104-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
AbstractNew aquaculture systems are emerging in new contexts around the world in part due to aquaculture’s perceived development benefits. However, linkages between aquaculture and food security in these systems are unclear. This study investigated the impact of emerging small-scale, business-oriented fish culture in central Bolivia on the food security and dietary diversity of aquaculture producers (n = 40) and workers (n = 26) in the value chain and compared them to local non-aquaculture farmers (n = 40). Three pathways were investigated: fish consumption, household income, and women’s participation. Food insecurity was widespread and did not vary in a statistically significant way between groups, but a trend toward greater food security amongst aquaculture producers was observed. Dietary diversity was highly homogenous, with the notable exception of high fish consumption amongst producers. Aquaculture was related to higher income, and income has a modest positive effect on food security for aquaculturists and non-aquaculture farmers, but not aquaculture value chain workers. Income did not have an effect on dietary diversity. Women’s involvement in aquaculture was correlated positively to productivity, profitability, and size of operation, while male-only aquaculture was negatively correlated to these. The value chain generated employment, especially for women, but average wages were higher for men. The research provides important insight into aquaculture-food security linkages by showing that the introduction of small-scale business-oriented aquaculture systems can provide nutritious products for regional consumption and can have positive effects on food security but is not sufficient to change local dietary preferences more broadly.
Collapse
|
15
|
Corkery I, Irwin S, Quinn JL, Keating U, Lusby J, O'Halloran J. Changes in forest cover result in a shift in bird community composition. J Zool (1987) 2020. [DOI: 10.1111/jzo.12757] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- I. Corkery
- School of Biological, Earth and Environmental Sciences University College Cork Cork Ireland
| | - S. Irwin
- School of Biological, Earth and Environmental Sciences University College Cork Cork Ireland
| | - J. L. Quinn
- School of Biological, Earth and Environmental Sciences University College Cork Cork Ireland
| | - U. Keating
- School of Biological, Earth and Environmental Sciences University College Cork Cork Ireland
| | - J. Lusby
- Birdwatch Ireland Bullford Business Campus County Wicklow Ireland
| | - J. O'Halloran
- School of Biological, Earth and Environmental Sciences University College Cork Cork Ireland
| |
Collapse
|
16
|
Nayyar D, Kumarasinghe G, Irwin S, Sharma L, Premawardhana U, Rajaratnam R, Kadappu K. Five-Year Outcome Data from the Budyari Cardiology Outreach Program. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα WT and ERα MUT Breast Cancer. Cancer Discov 2018; 8:1176-1193. [PMID: 29991605 DOI: 10.1158/2159-8290.cd-17-1229] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 05/11/2018] [Accepted: 06/19/2018] [Indexed: 11/16/2022]
Abstract
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant breast cancer metastases continue to be dependent on ERα signaling, there remains a critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). In vitro comparisons of H3B-5942 with standard-of-care (SoC) and experimental agents confirmed increased antagonist activity across a panel of ERαWT and ERαMUT cell lines. In vivo, H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERαY537S breast cancer that was superior to fulvestrant. Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERαWT and ERαMUT cell lines and/or tumor models. In summary, H3B-5942 belongs to a class of orally available ERα covalent antagonists with an improved profile over SoCs.Significance: Nearly 30% of endocrine therapy-resistant breast cancer metastases harbor constitutively activating mutations in ERα. SERCA H3B-5942 engages C530 of both ERαWT and ERαMUT, promotes a unique antagonist conformation, and demonstrates improved in vitro and in vivo activity over SoC agents. Importantly, single-agent efficacy can be further enhanced by combining with CDK4/6 or mTOR inhibitors. Cancer Discov; 8(9); 1176-93. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047.
Collapse
Affiliation(s)
| | | | | | | | | | - Kiran Aithal
- Aurigene Discovery Technologies Ltd., Bangalore, Karnataka, India
| | | | | | | | | | | | | | | | | | | | - René Houtman
- PamGene International, Den Bosch, the Netherlands
| | - Sean Irwin
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | | | - Craig Karr
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | - Amy Kim
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | | | - Pavan Kumar
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | | | | | | | | | - Lesley-Ann Martin
- Breast Cancer Now, Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | | | | | | | | | | | - Sunil Pancholi
- Breast Cancer Now, Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | | | | | | | | | | | - Ricardo Ribas
- Breast Cancer Now, Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Amy Siu
- Eisai Inc., Andover, Massachusetts
| | | | | | | | | | - John Wang
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | | | | | - Shihua Yao
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | - Lihua Yu
- H3 Biomedicine, Inc., Cambridge, Massachusetts
| | | | | | - Ping Zhu
- H3 Biomedicine, Inc., Cambridge, Massachusetts.
| | | |
Collapse
|
18
|
Finci LI, Zhang X, Huang X, Zhou Q, Tsai J, Teng T, Agrawal A, Chan B, Irwin S, Karr C, Cook A, Zhu P, Reynolds D, Smith PG, Fekkes P, Buonamici S, Larsen NA. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action. Genes Dev 2018; 32:309-320. [PMID: 29491137 PMCID: PMC5859971 DOI: 10.1101/gad.311043.117] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 02/07/2018] [Indexed: 12/16/2022]
Abstract
In this study, Finci et. al. present the cryo-EM structure of the SF3b subcomplex (SF3B1, SF3B3, PHF5A, and SF3B5), part of the U2 snRNP, bound to E7107 at 3.95 A. The structure suggests a model in which splicing modulators interfere with branch point adenosine recognition and supports a substrate competitive mechanism of action. Somatic mutations in spliceosome proteins lead to dysregulated RNA splicing and are observed in a variety of cancers. These genetic aberrations may offer a potential intervention point for targeted therapeutics. SF3B1, part of the U2 small nuclear RNP (snRNP), is targeted by splicing modulators, including E7107, the first to enter clinical trials, and, more recently, H3B-8800. Modulating splicing represents a first-in-class opportunity in drug discovery, and elucidating the structural basis for the mode of action opens up new possibilities for structure-based drug design. Here, we present the cryogenic electron microscopy (cryo-EM) structure of the SF3b subcomplex (SF3B1, SF3B3, PHF5A, and SF3B5) bound to E7107 at 3.95 Å. This structure shows that E7107 binds in the branch point adenosine-binding pocket, forming close contacts with key residues that confer resistance upon mutation: SF3B1R1074H and PHF5AY36C. The structure suggests a model in which splicing modulators interfere with branch point adenosine recognition and supports a substrate competitive mechanism of action (MOA). Using several related chemical probes, we validate the pose of the compound and support their substrate competitive MOA by comparing their activity against both strong and weak pre-mRNA substrates. Finally, we present functional data and structure–activity relationship (SAR) on the PHF5AR38C mutation that sensitizes cells to some chemical probes but not others. Developing small molecule splicing modulators represents a promising therapeutic approach for a variety of diseases, and this work provides a significant step in enabling structure-based drug design for these elaborate natural products. Importantly, this work also demonstrates that the utilization of cryo-EM in drug discovery is coming of age.
Collapse
Affiliation(s)
- Lorenzo I Finci
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Xiaofeng Zhang
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Xiuliang Huang
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Qiang Zhou
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Jennifer Tsai
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Teng Teng
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Anant Agrawal
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Betty Chan
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Sean Irwin
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Craig Karr
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Andrew Cook
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Ping Zhu
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | | | - Peter G Smith
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | - Peter Fekkes
- H3 Biomedicine, Inc., Cambridge, Massachusetts 02139, USA
| | | | | |
Collapse
|
19
|
Korpal M, Puyang X, Furman C, Zheng GZ, Banka D, Wu J, Zhang Z, Thomas M, Mackenzie C, Yao H, Rimkunas V, Kumar P, Caleb B, Karr C, Subramanian V, Irwin S, Larsen N, Vaillancourt F, Nguyen TV, Davis A, Chan B, Hao MH, O'Shea M, Prajapati S, Agoulnik S, Kuznetsov G, Kumar N, Yu Y, Lai G, Hart A, Eckley S, Fekkes P, Bowser T, Joshi JJ, Selvaraj A, Wardell S, Norris J, Smith S, Reynolds D, Mitchell L, Wang J, Yu L, Kim A, Rioux N, Sahmoud T, Warmuth M, Smith PG, Zhu P. Abstract P1-10-08: Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-10-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mutations in estrogen receptor alpha (ERα) are detected in up to 30% of breast cancer patients who have relapsed during endocrine therapy. ERα mutations functionally confer resistance to existing classes of endocrine therapies, likely through gaining constitutive activity. The fact that current ER-directed therapies are only partially effective in the ERα mutant setting, and that a significant proportion of resistant breast cancer metastases continue to remain dependent on ERα signaling for growth/survival, highlights the critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Using structure-based drug design approaches we have identified a novel class of ERα antagonist referred to as Selective ERα Covalent Antagonist (SERCA) that inactivate both wild-type and mutant ERα by targeting a unique cysteine residue that is not conserved among other steroid hormone receptors. Biophysical, biochemical and cellular analyses confirm the covalent mechanism of action, specific binding to ER and selective inhibition of ERα-dependent transcription of SERCAs. H3B-6545 is a highly selective SERCA that potently antagonizes wild-type and mutant ERα in biochemical and cell based assays demonstrating increased potency over standard of care and other experimental agents. In vivo, H3B-6545 shows superior efficacy to fulvestrant in the MCF-7 xenograft model with once daily oral dosing, achieving maximal antitumor activity at doses >10x below the maximum tolerated dose in mice. In addition, H3B-6545 shows superior antitumor activity to both tamoxifen and fulvestrant in patient derived xenograft models of breast cancer carrying estrogen receptor mutations. In summary, H3B-6545 is a first-in-class, orally available and selective ER covalent antagonist with a compelling pre-clinical profile that is being developed for the treatment of ERα positive breast cancer.
Citation Format: Korpal M, Puyang X, Furman C, Zheng GZ, Banka D, Wu J, Zhang Z, Thomas M, Mackenzie C, Yao H, Rimkunas V, Kumar P, Caleb B, Karr C, Subramanian V, Irwin S, Larsen N, Vaillancourt F, Nguyen T-V, Davis A, Chan B, Hao MH, O'Shea M, Prajapati S, Agoulnik S, Kuznetsov G, Kumar N, Yu Y, Lai G, Hart A, Eckley S, Fekkes P, Bowser T, Joshi JJ, Selvaraj A, Wardell S, Norris J, Smith S, Reynolds D, Mitchell L, Wang J, Yu L, Kim A, Rioux N, Sahmoud T, Warmuth M, Smith PG, Zhu P. Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-10-08.
Collapse
Affiliation(s)
- M Korpal
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - X Puyang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Furman
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - GZ Zheng
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - D Banka
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Wu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - Z Zhang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M Thomas
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Mackenzie
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - H Yao
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - V Rimkunas
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Kumar
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - B Caleb
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Karr
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - V Subramanian
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Irwin
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Larsen
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - F Vaillancourt
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T-V Nguyen
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Davis
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - B Chan
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - MH Hao
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M O'Shea
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Prajapati
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Agoulnik
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - G Kuznetsov
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Kumar
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - Y Yu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - G Lai
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Hart
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Eckley
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Fekkes
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T Bowser
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - JJ Joshi
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Selvaraj
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Wardell
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Norris
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Smith
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - D Reynolds
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - L Mitchell
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Wang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - L Yu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Kim
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Rioux
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T Sahmoud
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M Warmuth
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - PG Smith
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Zhu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| |
Collapse
|
20
|
Raman S, Ruston S, Irwin S, Tran P, Hotton P, Thorne S. Taking culture seriously: Can we improve the developmental health and well-being of Australian Aboriginal children in out-of-home care? Child Care Health Dev 2017; 43:899-905. [PMID: 28736897 DOI: 10.1111/cch.12488] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 06/19/2017] [Accepted: 06/22/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND Children in out-of-home care have well-documented health and developmental needs. Research suggests that Aboriginal children in care have unmet health and intervention needs. In metropolitan Sydney, Kari Aboriginal Resources Inc. (KARI), an Aboriginal organization, provides support to indigenous children in care, including clinical assessment and intervention. We wanted to determine the health and developmental needs of a subset of children in out-of-home care with KARI, who had been in stable care for at least a year. We wanted to identify child, carer, and intervention characteristics that contributed to children doing well. We also wanted to identify enablers and barriers to providing culturally competent intervention. METHODS We used mixed methods. From the KARI clinic database over the past 3 years, we identified children who had been in stable care with KARI for >12 months. We compared clinical measures and outcomes for these children with results from previous audits. We carried out a group discussion and key informant interviews with therapists and caseworkers to identify risk and resilience factors for each child, as well as enablers and barriers to culturally competent intervention. RESULTS The health and developmental profile of the 26 children identified as being in stable care was similar to that of previous audits. Most (88%) were getting speech pathology intervention; one third were getting occupational therapy and psychological intervention; most children and their carers attended cultural programmes. The majority of children (25/26) improved in their developmental health. Caseworkers and therapists identified risk and resilience factors related to child, carer, and home characteristics. They also identified elements of good practice; systemic issues prevented some interventions from being carried out. CONCLUSIONS There are challenges delivering a trauma-informed, culturally respectful service to Aboriginal children in out-of-home care in an urban setting, but it can be done if attention is paid to culture and the enablers and barriers are identified.
Collapse
Affiliation(s)
- S Raman
- Department of Community Paediatrics, South Western Sydney Local Health District, Liverpool, NSW, Australia.,School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia
| | - S Ruston
- Kari Aboriginal Resources Inc., Liverpool, NSW, Australia.,Allied Health Department, Liverpool Hospital, Liverpool, NSW, Australia
| | - S Irwin
- Kari Aboriginal Resources Inc., Liverpool, NSW, Australia
| | - P Tran
- Kari Aboriginal Resources Inc., Liverpool, NSW, Australia.,Allied Health Department, Liverpool Hospital, Liverpool, NSW, Australia
| | - P Hotton
- Child Protection Unit, Sydney Children's Hospital, Randwick, NSW, Australia
| | - S Thorne
- Kari Aboriginal Resources Inc., Liverpool, NSW, Australia
| |
Collapse
|
21
|
Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nat Commun 2017; 8:103. [PMID: 28740126 PMCID: PMC5524640 DOI: 10.1038/s41467-017-00147-w] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 06/05/2017] [Indexed: 12/12/2022] Open
Abstract
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority of patients fail to respond, suggesting existence of complementary immune evasion mechanisms. Here, we report that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion in MIBC. Recurrent mutations in RXRα at serine 427 (S427F/Y), through conformational activation of the PPARγ/RXRα heterodimer, and focal amplification/overexpression of PPARγ converge to modulate PPARγ/RXRα-dependent transcription programs. Immune cell-infiltration is controlled by activated PPARγ/RXRα that inhibits expression/secretion of inflammatory cytokines. Clinical data sets and an in vivo tumor model indicate that PPARγHigh/RXRαS427F/Y impairs CD8+ T-cell infiltration and confers partial resistance to immunotherapies. Knockdown of PPARγ or RXRα and pharmacological inhibition of PPARγ significantly increase cytokine expression suggesting therapeutic approaches to reviving immunosurveillance and sensitivity to immunotherapies. Our study reveals a class of tumor cell-intrinsic "immuno-oncogenes" that modulate the immune microenvironment of cancer.Muscle-invasive bladder cancer (MIBC) is a potentially lethal disease. Here the authors characterize diverse genetic alterations in MIBC that convergently lead to constitutive activation of PPARgamma/RXRalpha and result in immunosurveillance escape by inhibiting CD8+ T-cell recruitment.
Collapse
Affiliation(s)
- Manav Korpal
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
| | - Xiaoling Puyang
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Zhenhua Jeremy Wu
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Roland Seiler
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Craig Furman
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Htoo Zarni Oo
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Michael Seiler
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Sean Irwin
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | | | - Jaya Julie Joshi
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Chris K Wang
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Victoria Rimkunas
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Davide Tortora
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Hua Yang
- Eisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA
| | - Namita Kumar
- Eisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA
| | | | | | - Jesse Chow
- Eisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA
| | - Pavan Kumar
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Jian Zou
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Jacob Feala
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Laura Corson
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Ryan Henry
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Anand Selvaraj
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Allison Davis
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Kristjan Bloudoff
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - James Douglas
- Department of Urology, University Hospital of Southampton, Hampshire, SO16 6YD, UK
| | - Bernhard Kiss
- Department of Urology, University of Bern, Bern, CH-3010, Switzerland
| | - Morgan Roberts
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Ladan Fazli
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Peter C Black
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Peter Fekkes
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Peter G Smith
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Markus Warmuth
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Lihua Yu
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Ming-Hong Hao
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Nicholas Larsen
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA
| | - Mads Daugaard
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.,Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
| | - Ping Zhu
- H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
| |
Collapse
|
22
|
Rajaratnam D, Irwin S, Espino-Woo K, Harvey J, Jones N, Pomeroy W, Kadappu K, Rajaratnam R. Targeted Health Care Delivery Addresses Health Inequities in Disadvantaged Patients. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
23
|
Irwin S, Midgley A, Wright R, Peak M, Beresford M. FRI0007 Effect of Type 1 and 2 Interferons on Neutrophil Apoptosis in naÏve and TNF Alpha Primed Neutrophils. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Yaneza MMC, Hunter K, Irwin S, Kubba H. Hearing in school-aged children with trisomy 21 - results of a longitudinal cohort study in children identified at birth. Clin Otolaryngol 2016; 41:711-717. [PMID: 26663508 DOI: 10.1111/coa.12606] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/06/2015] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To report the prevalence of hearing problems and the hearing sequelae in school-aged children with trisomy 21 in a longitudinal study. DESIGN All children with trisomy 21 were identified via schools, community-based child development centres, general practitioners, or the universal newborn hearing screen. Audiological data and otorhinolaryngological problems were prospectively entered in to the Audiological Surveillance Programme database from each visit. SETTING Retrospective review of the Audiological Surveillance Programme database in the Glasgow area (United Kingdom) of all children reviewed between 2004 and 2012. PARTICIPANTS All pre-teenaged children with trisomy 21 of school age (aged 5-12 years old). MAIN OUTCOME MEASURES Hearing thresholds, aetiology of hearing loss and management of hearing loss was determined for the cohort of children. RESULTS A total of 102 children were included. Fifty-four had normal hearing. Twenty-six had fluctuating otitis media with effusion; five had hearing in normal limits, six were managed with hearing aids, fourteen were managed conservatively, and one had ventilation tube insertion. Fifteen had persistent otitis media with effusion; four had ventilation tube insertion; and nine were managed with hearing aids. Seven had mixed hearing loss with four required hearing aids. CONCLUSIONS Otitis media with effusion was the commonest cause of hearing impairment; effusions may fluctuate through the pre-teenaged years, and thus, hearing aids are beneficial. Ventilation tube insertion and bone-conducting hearing aids were useful when ear-level hearing aids were not tolerated. Mixed hearing loss occurred in later years as sensorineural hearing loss developed on a background of otitis media with effusion.
Collapse
Affiliation(s)
- M M C Yaneza
- Department of Paediatric Otolaryngology, The Royal Hospital for Children, Queen Elizabeth University Hospital Campus, Govan, Glasgow, UK.,Department of Otolaryngology, Monklands Hospital, Airdrie, UK
| | - K Hunter
- Department of Paediatric Audiology, The Royal Hospital for Children, Queen Elizabeth University Hospital Campus, Govan, Glasgow, UK
| | - S Irwin
- Department of Paediatric Otolaryngology, The Royal Hospital for Children, Queen Elizabeth University Hospital Campus, Govan, Glasgow, UK
| | - H Kubba
- Department of Paediatric Otolaryngology, The Royal Hospital for Children, Queen Elizabeth University Hospital Campus, Govan, Glasgow, UK
| |
Collapse
|
25
|
Irwin S, Midgley A, Beresford M. AB0073 Effects of Interferon Alpha on Neutrophil Apoptosis and Caspase 3 Cleavage. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Ronan DM, Folwell A, Irwin S. 11 * IMPROVING ADVANCE CARE PLANNING IN NURSING HOME RESIDENTS ADMITTED TO HOSPITAL. Age Ageing 2015. [DOI: 10.1093/ageing/afv029.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Sun K, DeMarco SJ, Guerlavais V, Mukherjee A, Irwin S, Shi E, Cai H, Darlak K, Santiago S, Pero J, Olson KA, Nash HM, Chang Y. Abstract LB-304: ATSP-9172, a novel Stapled Peptide inhibitor of HIF-dependent transcriptional activity with in vivo antitumor efficacy in a preclinical model of prostate cancer. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-lb-304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Hypoxia-inducible transcription factors (HIF) are key regulators of cellular adaptation to hypoxia in solid tumors, and HIF-1α controls the expression of genes involved in anaerobic metabolism, angiogenesis, cell growth and survival. Hydrocarbon cross-linked alpha helical peptides (Stapled Peptides) are a breakthrough approach to create new class of drugs that modulate intracellular protein-protein interactions. Here, we have mimicked the structure and function of the CITED2 protein, an endogenous negative regulator of the interaction between HIF-1α and p300 proteins, by designing a Stapled Peptide derived from CITED2 to generate the first example of a potent and selective Stapled Peptide inhibitor of HIF-1α-dependent transcription. ATSP-9172 bound to the CH1 domain of p300 and disrupted the HIF-1α C-TAD/CH1 interaction in biochemical assays and inhibited HIF-dependent reporter gene activity in ME-180 cells. Examination of endogenous transcript levels in ME-180 cells revealed that ATSP-9172 down-regulated the transcription of HIF-1α target genes, such as adolase C, angiopoietin-like 4, and carbonic anhydrase 9 in a dose-dependent manner, but did not affect the expression of non-HIF target genes, verifying a specific and on-target mechanism of action. ATSP-9172 exhibited a dramatic improvement in solubility and plasma stability profile relative to the linear peptide, and demonstrated favorable pharmacokinetic properties in mice by providing high systemic exposure, low plasma clearance and long elimination half-life. Finally, intravenous administration of ATSP-9172 on an every other day schedule significantly inhibited tumor growth in a PC-3 human prostate tumor xenograft model (p < 0.05); this inhibition was found to be dose-dependent. Our results demonstrate that a Stapled Peptide mimicking the HIF inhibitory function of the native CITED2 protein provides a novel and specific strategy to suppress HIF-1α-dependent gene expression for cancer therapy.
Citation Format: Kaiming Sun, Steven J. DeMarco, Vincent Guerlavais, Aditi Mukherjee, Sean Irwin, Eric Shi, Hongliang Cai, Krzysztof Darlak, Solimar Santiago, Jessica Pero, Karen A. Olson, Huw M. Nash, Yong Chang. ATSP-9172, a novel Stapled Peptide inhibitor of HIF-dependent transcriptional activity with in vivo antitumor efficacy in a preclinical model of prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-304. doi:10.1158/1538-7445.AM2013-LB-304
Collapse
Affiliation(s)
| | | | | | | | | | - Eric Shi
- Aileron Therapeutics, Cambridge, MA
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Saeed A, Khan M, Irwin S, Fraser A. Sarcoidosis presenting with severe hypocalcaemia. Ir J Med Sci 2009; 180:575-7. [DOI: 10.1007/s11845-009-0277-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Accepted: 01/06/2009] [Indexed: 11/28/2022]
|
29
|
Prescott SL, Irwin S, Taylor A, Roper J, Dunstan J, Upham JW, Burgner D, Richmond P. Cytosine-phosphate-guanine motifs fail to promote T-helper type 1-polarized responses in human neonatal mononuclear cells. Clin Exp Allergy 2005; 35:358-66. [PMID: 15784116 DOI: 10.1111/j.1365-2222.2005.02187.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND The T-helper type 1 (Th1) trophic properties of bacterial cytosine-phosphate-guanine (CpG) motifs have made them logical adjuvants both for the suppression of Th2-mediated allergic disease in early life and for promoting vaccine responses in neonates who have relatively immature Th1 function. However, little is known about their effects on immature immune responses in this period. OBJECTIVES To compare the effects of CpG on adult and neonatal cellular immune responses to various stimuli. METHODS The immune responses of mononuclear cells (MC) derived from neonates (n=25) and their mothers (n=25) were compared in vitro. These were stimulated with house dust mite (HDM), CpG B, CpG C, non-CpG oligodeoxynucleotides (ODN) or diphtheria toxoid (DT) in optimized conditions. In parallel cultures, CpGs were combined with HDM or DT antigens to assess the effect of the various ODN on these antigen-specific responses. Lymphoproliferation and cytokine responses IL-13, IFN-gamma, IL-6, IL-10, TNF-alpha) were measured for all of the cultures described above. RESULTS Although neonates showed attenuated lymphoproliferation to CpG, the production of antigen-presenting cell-derived cytokines such as IL-6 and IL-10 and the up-regulation of major histocompatibility complex class II (HLA-DR) were detected at adult levels. T cell-derived cytokines (IL-13 and IFN-gamma) were not detectable in response to CpG alone. Most neonates also failed to produce detectable IFN-gamma to HDM or DT (unlike adults), but readily produced IL-13 to these stimuli. The addition of CpG resulted in an increase in neonatal IFN-gamma production in response to HDM (P=0.011) and a similar but non-significant trend with DT. However, rather than inhibiting Th2 IL-13 responses, the addition of CpGs was associated with a significant increase in the IL-13 responses to HDM (P=0.016) and DT (P=0.03), effects not seen in adults. CONCLUSIONS This study provides further evidence that neonatal MC responses to CpG are functionally different from adults, and do not show clear Th1 polarization. The CpG associated increase in Th2 responses may reflect a potentiation of the normal neonatal Th2 propensity, or non-specific activation of neonatal MC.
Collapse
Affiliation(s)
- S L Prescott
- School of Paediatrics and Child Health Research, University of Western Australia, Perth, WA 6001, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
BACKGROUND The MicroMed DeBakey ventricular assist device (VAD) (MicroMed Technology, Inc, Houston, TX) is the first long-term axial flow circulatory assist device to be introduced into clinical trials as a bridge to transplantation. Clinical trials began in Europe in November 1998 and in the United States in June 2000. METHODS To qualify for the study, the patients must be listed for cardiac transplantation and must have demonstrated profound cardiac failure. There were no exclusions to the MicroMed DeBakey VAD implant other than those patients who would typically be excluded from cardiac transplantation. RESULTS As of September 2000, 51 patients have been implanted with the MicroMed DeBakey VAD. A detailed evaluation of the first 32 patients has been completed. With current data, the probability of survival at 30 days after VAD implant is 81%. CONCLUSIONS The clinical trial demonstrated that the MicroMed DeBakey VAD is capable of providing adequate circulatory support in patients with severe heart failure, sufficient to recover and return to normal activities while awaiting a heart transplantation. Much has been learned about the function of the device and its continuous flow in humans.
Collapse
Affiliation(s)
- G P Noon
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA.
| | | | | | | | | | | |
Collapse
|
31
|
Noon GP, Morley D, Irwin S, Abdelsayed S, Benkowski R, Lynch BE. Turbine blood pumps. Adv Card Surg 2001; 13:169-91. [PMID: 11209655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
After years of development and preclinical testing, clinical trials of the MicroMed DeBakey VAD began in November 1998 in Europe and in June 2000 in the United States. As of August 2000, 44 patients in Europe and 3 patients in the United States have undergone implantation with the MicroMed DeBakey VAD. In conclusion, data from the European clinical trial of the MicroMed DeBakey VAD support the safety and performance of the device. Results show that the device provides adequate left ventricular and circulatory support in patients with end-stage heart failure without unduly jeopardizing patient safety. Moreover, the device provides advantages not inherent to commercially available pulsatile devices: (1) miniature size, enabling implantation in smaller patients; (2) ease of implantation; (3) reduced surgical bleeding; and (4) a low incidence of postoperative infections, often a limiting factor with other devices. The MicroMed DeBakey VAD European clinical trial is the first demonstration of the compatibility of continuous blood flow with adequate tissue perfusion and overall maintenance of life for up to 4.5 months. This initial experience with the MicroMed DeBakey VAD suggests that the pump can provide circulatory support to bridge patients to cardiac transplantation and may provide an improved quality of life for the patient with end-stage heart failure.
Collapse
Affiliation(s)
- G P Noon
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA
| | | | | | | | | | | |
Collapse
|
32
|
Irwin S. A view to the future. Phys Ther 2000; 80:715-6. [PMID: 10869136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
33
|
Irwin S. Different method, different results? Phys Ther 2000; 80:622-4. [PMID: 10842415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
34
|
Abstract
This paper explores recent arguments about the marketization of female labour, in the context of a wider analysis of the role of concepts like 'the market' and 'individualization' in sociological accounts of change in employment relations. It will be argued that within sociology there has been a tendency for rapid, large-scale changes in employment relations to be characterized as the breakdown of social influences or structures and as the emergence of atomized, individuated market forces. In the most recent models, change in the nature of gendered positions within employment are presented in terms of a decline of social structuring and social constraint. These emergent accounts hold similarities to classical economics, and to Marx's and Weber's accounts of employment, which also characterized new forms of employment relations in terms of the emptying of their social content and their replacement by market forms. We offer an alternative, moral economy, perspective which foregrounds the continued significance of social relations in the structuring of employment and employment change. We develop the argument through an analysis of gendered patterns of employment and change in family form.
Collapse
Affiliation(s)
- S Irwin
- Department of Sociology and Social Policy, University of Leeds
| | | |
Collapse
|
35
|
Abstract
A miniaturized axial flow pump to provide left ventricular assistance has been developed. Such a device has the potential to address limitations of the larger pulsatile devices. Clinical trials of the MicroMed DeBakey VAD (ventricular assist device) began in Europe in November 1998. As of December 1, 1999, 18 patients have been implanted with the MicroMed DeBakey VAD. Hemodynamic evaluations along with blood chemistry analysis were recorded routinely. Exercise tolerance was observed. In most patients, end-organ function has improved and has not deteriorated in any patient. Patients have been able to perform normal low-level activity and have tolerated positional changes without evidence of postural hemodynamic changes. Select patients have taken supervised out-of-hospital excursions. This initial clinical experience with the MicroMed DeBakey VAD suggests that the miniaturized axial flow pump can provide ventricular support to bridge patients to cardiac transplant and may provide an improved quality of life for the end-stage heart failure recipient.
Collapse
Affiliation(s)
- G P Noon
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | |
Collapse
|
36
|
Irwin S, Kenny AP, O'Halloran J, FitzGerald RD, Duggan PF. Adaptation and validation of a radioimmunoassay kit for measuring plasma cortisol in turbot. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1999; 124:27-31. [PMID: 10579645 DOI: 10.1016/s0742-8413(99)00043-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Levels of cortisol in fish blood provide quantitative information on the degree of stress induced by a variety of stressors. It is also useful in describing the social status of individual fish within groups. The commercial production of radioimmunoassay (RIA) kits, such as the DPC Coat-A-Count radioimmunoassay kit, has considerably reduced the effort required for cortisol measurement. These kits employ human plasma based cortisol standards which are not compatible for use with non mammalian species such as fish e.g. turbot, Scophthalmus maximus (Rafinesque), blood due to the interference effect of lipids and steroid binding proteins present in the plasma. In this study the DPC kit was used following the removal of these lipids and steroid binding proteins from the plasma using an ethanol-hexane extraction. Excessive variability in the cortisol values obtained using this method deemed it unsatisfactory in overcoming the problem of incompatibility. A second modification of this technique that was tested involved the preparation of turbot specific standards for use in the preparation of modified standard curves. Using this method, an accuracy of 93.4% was achieved, as opposed to 79.6% using the kit human plasma based standards, and 47.1% using samples following lipid removal using an ethanol-hexane extraction. Based on analysis of accuracy, precision and reproducibility it is concluded that commercially available cortisol kits are suitable for use with turbot plasma, but a number of minor modifications are necessary.
Collapse
Affiliation(s)
- S Irwin
- Aquaculture Development Centre, Department of Zoology and Animal Ecology, University College, Cork, Ireland
| | | | | | | | | |
Collapse
|
37
|
|
38
|
Abstract
BACKGROUND Short-term ventricular and pulmonary support can be provided by the Medtronic BioMedicus (Eden Prairie, MN) centrifugal pump, which is available in most cardiovascular surgery centers. This versatile pump can provide support during cardiopulmonary resuscitation, cardiopulmonary bypass, extracorporeal membrane oxygenation, and ventricular assistance. A common use of the pump is to provide ventricular assistance for patients after cardiotomy or cardiogenic shock. METHODS From January 1986 to September 1995, 141 patients at The Methodist Hospital in Houston, Texas were placed on the BioMedicus centrifugal pump after postcardiotomy cardiac failure. Patient treatment and postimplant complications are discussed. RESULTS Fifty-four percent of the patients were weaned; however, only 22% survived to discharge. There was a very high mortality rate in the early stage after support was discontinued, after weaning, and after device removal. CONCLUSIONS A high incidence of complications and death is likely related to the period of attempted weaning from cardiopulmonary bypass before the initiation of ventricular support. When weaning a patient from the pump during cardiopulmonary bypass or during ventricular assistance, it is important to optimize preload, after-load, ventricular function, and cardiac rhythm. In patients who have had postcardiotomy support, avoiding fluid overload, low colloid oncotic pressure, hypoperfusion, and use of excessive inotropic and vasoactive medications improve results.
Collapse
Affiliation(s)
- G P Noon
- Department of Surgery, Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA
| | | | | |
Collapse
|
39
|
|
40
|
Irwin S. Age related distributive justice and claims on resources. Br J Sociol 1996; 47:68-92. [PMID: 8680793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The ageing population structure, and claims on resources by non-working groups, are seen by many to be contributing to a growing welfare crisis. In their arguments, relations between age groups and generations will become increasingly fraught, and welfare arrangements will be undermined, as 'unacceptable' levels of taxation blight the experience of a contracting workforce, required to resource a growing welfare population. However, more seems to be known about researchers' views on distributive justice than is known about the perceptions of their subject populations. It has not been demonstrated that members of age groups share interests which are consonant with their cohort experience, or perceive their interests to be in conflict with those members of other age groups or generations. This paper analyses empirical evidence on people's perceptions of who should get, and do, what, in developing an argument that standard processes do not place age groups or generations in antagonistic relationship. Understanding the relations between age groups and generations is essential to explaining change in patterns of inequality, but the interdependence of these relations suggest that they are part of a coherent social structure, and not likely to give rise to crisis in the ways predicted.
Collapse
Affiliation(s)
- S Irwin
- School of Sociology and Social Policy, University of Leeds
| |
Collapse
|
41
|
Abstract
The Cre protein of bacteriophage P1 is a 38.5 kDa site-specific recombinase that belongs to the Int family of recombination proteins. Cre acts by binding specifically to a 34 base-pair sequence, lox, where it carries out recombination. A limited chymotryptic digest of Cre resulted in two fragments of sizes 25 and 13.5 kDa, respectively. The sequence of the amino terminus of the purified 25 kDa peptide demonstrates that this peptide represents the carboxyl-terminal portion of the Cre protein. A truncated version of the cre gene was constructed which produces only the 25 kDa peptide. The 25 kDa peptide is capable of specific binding to the lox site, but binds at lower affinity than does wild-type Cre. Footprinting with Fe-EDTA indicates that the 25 kDa peptide protects the inverted repeats of the lox site but shows only partial protection of the spacer region. This is in contrast to the footprint obtained with wild-type Cre which protects the entire spacer region.
Collapse
Affiliation(s)
- R Hoess
- E.I. du Pont de Nemours & Co., Inc., Central Research and Development Department, Wilmington, DE 19880-0328
| | | | | | | | | |
Collapse
|
42
|
Abstract
Non-compliance with medical advice is poorly understood. Most of the existing literature considers the problem only from the doctor's point of view. We undertook a diachronic, qualitative study of the illness experiences of 19 women to try to understand non-compliance from the patient's perspective. Three-fourths of our study group had ceased to follow their doctor's recommendations by four months post-diagnosis. Their non-compliance could not be explained by the fact that the women held understandings of their illnesses which were incongruent with their physician's; nor were they unable to understand the diagnosis they received. A consideration of the roles that their diagnosis and treatments played in their daily lives proved more useful in explaining their failure to follow physicians' recommendations. Patients' use of treatments reflected their desire to control symptoms within the constraints of their daily routines.
Collapse
Affiliation(s)
- L M Hunt
- Department of Anthropology, Harvard University, Cambridge, Mass 02138
| | | | | | | |
Collapse
|
43
|
Abstract
A group of women were interviewed about their construction of their illness experiences before they saw a physician and subsequently over a period of several months following consultation. It was found that the physician's input was one of many components of their post-consultation understanding of their illnesses. The women built up their understandings in an interactive process, drawing significantly on their prior histories, ongoing experiences and social worlds. They continually tried out, adjusted and reworked the construction of their illnesses to adapt them to the exigencies of everyday life. We conclude that illness explanations are dynamic entities whose adequacy is determined by their usefulness within the extra-medical social environment.
Collapse
Affiliation(s)
- L M Hunt
- Department of Anthropology, Harvard University, Cambridge, MA 02138
| | | | | |
Collapse
|
44
|
Abstract
This article reviews five clinical techniques for measuring and assessing the manifestations of ischemic heart disease. These measurements are heart rate, blood pressure, electrocardiogram, symptoms, and changes in heart sounds. The data obtained from these measurements are discussed in relation to measurement accuracy and to their clinical significance and relationship with the patient's diagnosis, prognosis, and disease manifestations. These clinical measures provide information that is critical to the decision-making processes for patient programming and safety.
Collapse
|
45
|
|
46
|
Irwin S. Video variety at the Kettering Medical Center. Educ Ind Telev 1981; 13:68-72. [PMID: 10252993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
47
|
Irwin S, Blachly PH, Marks J, Carlson E, Loewen J, Reade N. The behavioral, cognitive and physiologic effects of long-term methadone and methadyl treatment. 1973 [proceedings]. NIDA Res Monogr 1976:66-7. [PMID: 792699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
48
|
Irwin S, Kinohi RG, Cooler PM, Bottomly DR. Acute time-dose-response effects of cyclazocine, methadone, and methadyl in man. 1975 [proceedings]. NIDA Res Monogr 1976:70-1. [PMID: 792701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
49
|
Blachly PH, David NA, Irwin S. 1-Alpha-acetylmethadol (LAM): comparison of laboratory findings, electroencephalograms, and Cornell Medical Index of patients stabilized on LAM with those on methadone. 1972 [proceedings]. NIDA Res Monogr 1976:57. [PMID: 995178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
50
|
Irwin S, Blachly P, Marks J, Carter CC. Preliminary observations with acute and chronic methadone and 1-alpha-acetylmethadol administration in humans. NIDA Res Monogr 1976:68-9. [PMID: 792700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|